These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Enzyme therapy in inherited enzymatic deficiencies: an approach to mucopolysaccharidoses. Pereira S; Toledo A Rev Hosp Clin Fac Med Sao Paulo; 1978 Apr; 33(2):73-5. PubMed ID: 96517 [No Abstract] [Full Text] [Related]
25. New prospects for the treatment of lysosomal storage diseases. Schiffmann R; Brady RO Drugs; 2002; 62(5):733-42. PubMed ID: 11929328 [TBL] [Abstract][Full Text] [Related]
26. [Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI]. Tóth J; Szücs FZ; Benkö K; Maródi L Orv Hetil; 2003 Apr; 144(16):749-55. PubMed ID: 12778625 [TBL] [Abstract][Full Text] [Related]
27. Protein structural features predict responsiveness to pharmacological chaperone treatment for three lysosomal storage disorders. Woodard J; Zheng W; Zhang Y PLoS Comput Biol; 2021 Sep; 17(9):e1009370. PubMed ID: 34529671 [TBL] [Abstract][Full Text] [Related]
28. Investigations in enzyme replacement therapy in lipid storage diseases. Brady RO; Pentchev PG; Gal AG Fed Proc; 1975 Apr; 34(5):1310-5. PubMed ID: 804420 [TBL] [Abstract][Full Text] [Related]
29. A charitable access program for patients with lysosomal storage disorders in underserved communities worldwide. Mehta A; Ramaswami U; Muenzer J; Giugliani R; Ullrich K; Collin-Histed T; Panahloo Z; Wellhoefer H; Frader J Orphanet J Rare Dis; 2021 Jan; 16(1):8. PubMed ID: 33407729 [TBL] [Abstract][Full Text] [Related]
30. Treatable lysosomal storage diseases in the advent of disease-specific therapy. Peters H; Ellaway C; Nicholls K; Reardon K; Szer J Intern Med J; 2020 Nov; 50 Suppl 4():5-27. PubMed ID: 33210402 [TBL] [Abstract][Full Text] [Related]
31. Enzyme replacement therapy in Gaucher's and Fabry's disease. Pentchev PG Ann Clin Lab Sci; 1977; 7(3):251-3. PubMed ID: 404951 [TBL] [Abstract][Full Text] [Related]
32. Therapy for lysosomal storage disorders. Beck M IUBMB Life; 2010 Jan; 62(1):33-40. PubMed ID: 20014233 [TBL] [Abstract][Full Text] [Related]
33. Cardiac challenges in patients with Fabry disease. Weidemann F; Linhart A; Monserrat L; Strotmann J Int J Cardiol; 2010 May; 141(1):3-10. PubMed ID: 19720409 [TBL] [Abstract][Full Text] [Related]
34. Efficacy of pentosan polysulfate in in vitro models of lysosomal storage disorders: Fabry and Gaucher Disease. Crivaro AN; Mucci JM; Bondar CM; Ormazabal ME; Ceci R; Simonaro C; Rozenfeld PA PLoS One; 2019; 14(5):e0217780. PubMed ID: 31150494 [TBL] [Abstract][Full Text] [Related]
35. Diagnostic and therapeutic applications of sphingolipid hydrolyzing enzymes. Brady RO Curr Top Cell Regul; 1985; 26():39-50. PubMed ID: 3935381 [No Abstract] [Full Text] [Related]
36. Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges. Desnick RJ; Schuchman EH Annu Rev Genomics Hum Genet; 2012; 13():307-35. PubMed ID: 22970722 [TBL] [Abstract][Full Text] [Related]
37. Emerging strategies for the treatment of hereditary metabolic storage disorders. Brady RO Rejuvenation Res; 2006; 9(2):237-44. PubMed ID: 16706651 [TBL] [Abstract][Full Text] [Related]
38. Velaglucerase alfa for the management of type 1 Gaucher disease. Morris JL Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444 [TBL] [Abstract][Full Text] [Related]
39. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy. Breunig F; Wanner C J Nephrol; 2008; 21(1):32-7. PubMed ID: 18264934 [TBL] [Abstract][Full Text] [Related]
40. Evaluation of endocrinological involvement and metabolic status in patients with Gaucher disease Type 1 and Fabry disease under enzyme replacement therapy. Ersoy M; Pişkinpaşa H J Pediatr Endocrinol Metab; 2022 Apr; 35(4):519-527. PubMed ID: 35245971 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]